
IDEAYA Biosciences Revenue | IDYA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue IDEAYA Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 219 M | 7 M | 23.4 M | 50.9 M | 27.9 M | 19.5 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 219 M | 7 M | 57.9 M |
Quarterly Revenue IDEAYA Biosciences
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.2 M | 8.86 M | 6.56 M | 10.9 M | 208 M | - | - | 7 M | - | - | - | - | 8.04 M | 3.54 M | 7.88 M | 4.02 M | 29.7 M | 5.85 M | 11.4 M | 2.96 M | 8.98 M | 8.76 M | 7.25 M | 10.6 M | 8.97 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 208 M | 2.96 M | 19.4 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Kala Pharmaceuticals
KALA
|
3.89 M | $ 2.73 | -9.61 % | $ 22.2 M | ||
|
Intellia Therapeutics
NTLA
|
67.7 M | $ 10.02 | 5.24 % | $ 1.09 B | ||
|
Adagene
ADAG
|
7.67 M | $ 1.8 | -10.56 % | $ 106 M | ||
|
Denali Therapeutics
DNLI
|
331 M | $ 18.43 | 1.29 % | $ 3.18 B | ||
|
Pfizer
PFE
|
62.6 B | $ 27.4 | -0.62 % | $ 156 B | ||
|
Amarin Corporation plc
AMRN
|
214 M | $ 10.56 | -6.26 % | $ 4.38 B | ||
|
ImmuCell Corporation
ICCC
|
27.6 M | $ 11.08 | -0.81 % | $ 100 M | ||
|
Editas Medicine
EDIT
|
40.5 M | $ 1.63 | -4.68 % | $ 145 M | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
678 M | $ 93.83 | 0.32 % | $ 6.96 B | ||
|
Agios Pharmaceuticals
AGIO
|
54 M | $ 27.54 | -4.24 % | $ 1.6 B | ||
|
Royalty Pharma plc
RPRX
|
2.38 B | $ 68.45 | 1.08 % | $ 29.4 B | ||
|
Equillium
EQ
|
41.1 M | $ 1.06 | -5.36 % | $ 60.7 M | ||
|
Black Diamond Therapeutics
BDTX
|
70 M | $ 1.32 | -5.04 % | $ 75.1 M | ||
|
Abeona Therapeutics
ABEO
|
5.82 M | $ 2.42 | -1.17 % | $ 128 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
1.07 B | $ 17.1 | -2.79 % | $ 2.88 B | ||
|
Atossa Therapeutics
ATOS
|
1.76 K | $ 1.6 | -8.86 % | $ 13.8 M | ||
|
Cleveland BioLabs, Inc.
CBLI
|
263 K | - | -7.31 % | $ 49 M | ||
|
Rhythm Pharmaceuticals
RYTM
|
190 M | $ 112.31 | -3.84 % | $ 7.3 B | ||
|
Five Prime Therapeutics, Inc.
FPRX
|
13.2 M | - | - | $ 1.77 B | ||
|
ADC Therapeutics SA
ADCT
|
81.4 M | $ 1.29 | -2.28 % | $ 164 M | ||
|
Harmony Biosciences Holdings
HRMY
|
868 M | $ 32.58 | -1.21 % | $ 1.87 B | ||
|
Ardelyx
ARDX
|
407 M | $ 2.99 | -2.25 % | $ 721 M | ||
|
Akebia Therapeutics
AKBA
|
236 M | $ 0.39 | -8.41 % | $ 100 M | ||
|
Alector
ALEC
|
21 M | $ 2.34 | 1.52 % | $ 241 M | ||
|
ALX Oncology Holdings
ALXO
|
1.18 M | $ 1.06 | 3.43 % | $ 56.9 M | ||
|
Amneal Pharmaceuticals
AMRX
|
3.02 B | $ 21.12 | -1.26 % | $ 6.62 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
14.1 M | $ 4.03 | -1.11 % | $ 772 M | ||
|
Agenus
AGEN
|
114 M | $ 5.97 | -2.85 % | $ 178 M | ||
|
AbCellera Biologics
ABCL
|
75.1 M | $ 9.63 | -8.02 % | $ 2.88 B | ||
|
Aptevo Therapeutics
APVO
|
3.11 M | $ 0.4 | -2.61 % | $ 126 K | ||
|
Aligos Therapeutics
ALGS
|
2.19 M | $ 1.22 | -2.4 % | $ 12.1 M | ||
|
Aclaris Therapeutics
ACRS
|
7.83 M | $ 3.44 | -1.86 % | $ 422 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
277 M | $ 27.46 | -2.1 % | $ 4.17 B | ||
|
Biofrontera AG
BFRA
|
30.3 M | - | -8.24 % | $ 105 M | ||
|
SIGA Technologies
SIGA
|
94.6 M | $ 2.4 | -9.06 % | $ 172 M | ||
|
Catabasis Pharmaceuticals, Inc.
CATB
|
500 K | - | -6.97 % | $ 657 M | ||
|
Capricor Therapeutics
CAPR
|
22.3 M | $ 7.56 | 0.4 % | $ 351 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 28.3 | 0.68 % | $ 1.32 B | ||
|
China Biologic Products Holdings, Inc.
CBPO
|
524 M | - | 1.68 % | $ 4.65 B | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
19.4 M | $ 55.64 | 2.88 % | $ 155 M | ||
|
Syndax Pharmaceuticals
SNDX
|
172 M | $ 8.71 | -4.16 % | $ 755 M | ||
|
Aquestive Therapeutics
AQST
|
44.5 M | $ 3.47 | -6.48 % | $ 371 M | ||
|
Pliant Therapeutics
PLRX
|
1.58 M | $ 0.59 | -4.42 % | $ 36.2 M | ||
|
Jaguar Health
JAGX
|
11.5 M | $ 0.24 | -27.06 % | $ 560 K | ||
|
Arvinas
ARVN
|
263 M | $ 6.41 | -4.9 % | $ 454 M | ||
|
Cerus Corporation
CERS
|
234 M | $ 1.86 | -2.37 % | $ 355 M |